Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Rhythm Pharmaceuticals IncRYTM | $111.18 | Strong Buy | $129.00 | +16.03% | a day ago | |
Analyst RankingTop 8% #408 out of 5067 analysts Average Return+13.4% Win Rate59%73 out of 123 Risk vs RewardPoor Good Analyst ColorMorgan Stanley's Jeffrey Hung raised their price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) by 5.7% from $122 to $129 on 2025/10/16. The analyst maintained their Strong Buy rating on the stock. Hung said they have confidence that Rhythm Pharmaceuticals' commercial success with Bardet-Biedl syndrome will pave the way for "meaningful label expansion" in hypothalamic obesity later this year. The analyst pointed out that the company has a PDUFA deadline on 2025/12/20. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to ? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.